Published in N Engl J Med on January 20, 2000
Impact of Diabetes on Left Ventricular Remodeling (P3) | NCT01052272
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | NCT00108706
Prevention of Ischemic Events in Patients With Peripheral Arterial Disease (PID-PAB) | NCT00761969
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med (2008) 9.50
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ (2004) 7.92
Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med (2007) 7.69
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet (2013) 5.20
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (2009) 4.73
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A (2006) 4.10
Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA (2011) 4.09
Insulin resistance and cardiovascular disease. J Clin Invest (2000) 4.05
Validity of composite end points in clinical trials. BMJ (2005) 3.26
Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension (2002) 3.23
Intention-to-treat principle. CMAJ (2001) 3.20
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest (2005) 2.59
Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ (2005) 2.57
Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest (2006) 2.33
Antioxidants in Translational Medicine. Antioxid Redox Signal (2015) 2.32
Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med (2005) 2.28
Insulin resistance and atherosclerosis. J Clin Invest (2006) 2.27
Population based screening for chronic kidney disease: cost effectiveness study. BMJ (2010) 2.19
Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord (2010) 2.19
Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation (2009) 2.09
Heart failure: epidemiology and prevention in India. Natl Med J India (2011) 2.09
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ (2009) 2.02
Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res (2010) 2.00
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension (2010) 1.94
The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ (2003) 1.94
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest (2006) 1.92
Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol (2013) 1.91
Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ (2010) 1.89
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med (2008) 1.83
Rapid assessment of chest pain. BMJ (2001) 1.82
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension (2009) 1.81
A qualitative study of evidence in primary care: what the practitioners are saying. CMAJ (2002) 1.80
The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int (2014) 1.80
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death. J Am Coll Cardiol (2011) 1.80
Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78
Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol (2010) 1.76
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int (2011) 1.74
Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice. Circulation (2010) 1.74
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
CaMKII in the cardiovascular system: sensing redox states. Physiol Rev (2011) 1.67
Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease. J Am Coll Cardiol (2016) 1.66
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension (2011) 1.65
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol (2004) 1.64
Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev (2012) 1.61
Drug treatment of hypertension. BMJ (2003) 1.59
Managing comorbidities in patients at the end of life. BMJ (2004) 1.59
ACE inhibition in cardiovascular disease. N Engl J Med (2000) 1.58
Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc (2010) 1.58
Diabetes care needs evidence based interventions to reduce risk of vascular disease. BMJ (2000) 1.57
Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension (2013) 1.55
Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med (2007) 1.54
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them! Curr Control Trials Cardiovasc Med (2000) 1.52
Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ (2007) 1.51
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation (2011) 1.51
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ (2008) 1.51
Impact of nicorandil in angina: subgroup analyses. Heart (2004) 1.50
Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract (2008) 1.49
Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. Diabetologia (2010) 1.49
Effect of blood pressure on 3-month functional outcome in the subacute stage of ischemic stroke. Neurology (2012) 1.48
Retracted The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice. PLoS One (2013) 1.47
Ramipril use in Canada: HOPE or HYPE? CMAJ (2003) 1.45
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites. J Am Coll Cardiol (2015) 1.45
Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med (2010) 1.44
Hypertension, diabetes and overweight: looming legacies of the Biafran famine. PLoS One (2010) 1.44
The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. Br J Clin Pharmacol (2006) 1.43
The impact of Medicare Part D on hospitalization rates. Health Serv Res (2011) 1.43
Modifications of coronary risk factors. Am J Cardiol (2006) 1.41
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Effect of vitamin D supplementation on blood pressure in blacks. Hypertension (2013) 1.39
Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Br J Clin Pharmacol (2008) 1.39
Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38
Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol (2000) 1.38
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer (2009) 1.38
Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov (2010) 1.38
Diabetes, diversity, and disparity: what do we do with the evidence? Am J Public Health (2002) 1.38
Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord (2006) 1.35
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol (2008) 1.34
What are the elements of good treatment for hypertension? BMJ (2001) 1.28
Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med (2014) 1.26
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart (2006) 1.26
Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis (2008) 1.26
Time trends in STEMI--improved treatment and outcome but still a gender gap: a prospective observational cohort study from the SWEDEHEART register. BMJ Open (2012) 1.26
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
The rapid formation of a large rotating disk galaxy three billion years after the Big Bang. Nature (2006) 6.44
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Reflex regulation of arterial pressure during sleep in man. A quantitative method of assessing baroreflex sensitivity. Circ Res (1969) 5.27
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth (2013) 4.60
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45
Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet (1996) 4.28
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77
Oxford and McKinsey: Cogwheel and beyond. Br Med J (1970) 3.50
Ramipril and the development of diabetes. JAMA (2001) 3.38
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet (1999) 3.01
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res (1971) 2.95
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76
Municipal waterborne giardiasis: an epidemilogic investigation. Beavers implicated as a possible reservoir. Ann Intern Med (1980) 2.69
Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13. Nature (2002) 2.59
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Effects of physical training in chronic heart failure. Lancet (1990) 2.54
Survival in frontotemporal dementia. Neurology (2003) 2.48
Diminished baroreflex sensitivity in high blood pressure. Circulation (1969) 2.40
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Candida endocarditis treated with 5-fluorocytosine. Br Med J (1971) 2.20
Cuff and ambulatory blood pressure in subjects with essential hypertension. Lancet (1981) 2.18
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension (2001) 2.15
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study. BMJ (2001) 2.08
Perioperative corticosteroid supplementation and dento-alveolar surgery. Dent Update (2003) 2.02
Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet (1980) 2.00
Change in cartilage morphometry: a sample of the progression cohort of the Osteoarthritis Initiative. Ann Rheum Dis (2008) 1.98
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Action potentials in fibres from receptors in the epicardium and myocardium of the dog's left ventricle. J Physiol (1965) 1.95
Continuous recording of direct arterial pressure and electrocardiogram in unrestricted man. Br Med J (1972) 1.91
Changes in autonomic regulation induced by physical training in mild hypertension. Hypertension (1988) 1.90
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet (1991) 1.88
Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation (1996) 1.88
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Invertase and disulphide bridges in the yeast wall. J Gen Microbiol (1970) 1.80
Effects of controlled breathing, mental activity and mental stress with or without verbalization on heart rate variability. J Am Coll Cardiol (2000) 1.79
Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology (1987) 1.77
ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation (1995) 1.75
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology (1988) 1.74
Simulation model for planning renal services in a district health authority. BMJ (1992) 1.73
Effects of autonomic blockade on the baroreflex in man at rest and during exercise. Circ Res (1972) 1.71
Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology (1983) 1.67
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology (1996) 1.64
Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 1.62
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology (1999) 1.62
Early rehabilitation after myocardial infarction. Lancet (1982) 1.60
The lung in patients with cirrhosis. J Hepatol (1990) 1.59
Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med (1997) 1.58
Effects of endurance training on baroreflex sensitivity and blood pressure in borderline hypertension. Lancet (1991) 1.58
Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br Med J (Clin Res Ed) (1981) 1.58
Cardiovascular, cerebrovascular, and respiratory changes induced by different types of music in musicians and non-musicians: the importance of silence. Heart (2005) 1.58
Cholesterol and total mortality: need for larger trials. BMJ (1992) 1.57
Cardiovascular and respiratory changes during sleep in normal and hypertensive subjects. Cardiovasc Res (1969) 1.57
Difficult tracheal intubation secondary to a tracheal diverticulum and a 90 degree deviation in the trachea. Anaesthesia (2000) 1.57
Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57
Direct arterial pressure, heart rate and electrocardiogram during human coitus. J Reprod Fertil (1974) 1.56
The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. Eur Heart J (1984) 1.55
Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol (1998) 1.55
Thrombocytopenia associated with legionnaires' disease. Br Med J (1978) 1.54
A review of evaluative studies of computer-based learning in nursing education. Nurse Educ Today (2001) 1.54
Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology (1988) 1.53
Chemosis following blepharoplasty: an unusual complication. Ophthalmic Surg (1995) 1.52